Abstract
Objective To present a study on the impact of a Methoexact sectum (MTX) dose on toxicity in oncopediatric patients. Study Design The collection of demographic and current disease in the patients was collected, extracted from the medical records and dental follow-up records. The degrees of hematological toxicity were graded according to the National Cancer Institute (NCI). Results In the present study, a higher incidence of hematological toxicity was observed in cycles that infused 5g/m², with neutropenia, anemia, and thrombocytopenia being the most frequent. Considering patients who infused 2.5 g/m2 of MTX, 10 cycles had oral mucositis. The toxicity of cycles that made 5 g/m2 varied according to infusion time. As for toxicity in other sites, mucositis grades I and II were the most common. There were 07 cycles that showed a delay in the elimination of MTX at hour 42; however, most of these cycles showed creatinine elevation from baseline pre-infusion values. In these cycles, there was a need to change the treatment with Leucovorin (LCV), with mucositis grade II being the most prevalent in these cases. Conclusion It can be observed that the higher the MTX dosage, the higher the incidence and severity of oral mucositis. To present a study on the impact of a Methoexact sectum (MTX) dose on toxicity in oncopediatric patients. The collection of demographic and current disease in the patients was collected, extracted from the medical records and dental follow-up records. The degrees of hematological toxicity were graded according to the National Cancer Institute (NCI). In the present study, a higher incidence of hematological toxicity was observed in cycles that infused 5g/m², with neutropenia, anemia, and thrombocytopenia being the most frequent. Considering patients who infused 2.5 g/m2 of MTX, 10 cycles had oral mucositis. The toxicity of cycles that made 5 g/m2 varied according to infusion time. As for toxicity in other sites, mucositis grades I and II were the most common. There were 07 cycles that showed a delay in the elimination of MTX at hour 42; however, most of these cycles showed creatinine elevation from baseline pre-infusion values. In these cycles, there was a need to change the treatment with Leucovorin (LCV), with mucositis grade II being the most prevalent in these cases. It can be observed that the higher the MTX dosage, the higher the incidence and severity of oral mucositis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have